Evidence map›Paper›PMID 41615925›Full record

ArticlePloS one2026

Uralenol, Glycyrol, and Abyssinone II as potent inhibitors of fibroblast growth factor receptor 2 from anti-cancer plants: A deep learning and molecular dynamics approach.

Alomgir Hossain, Md Sanowar Hossan, Md Shahanur Prodhan, Md Nahid Hasan Joy, Muntasir Rahman Siam, Md Ekhtiar Rahman, Mohammad Nurul Matin

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alomgir HossainComputational Biosciences and Chemistry Research Organization, Rajshahi, Bangladesh.ORCID https://orcid.org/0000-0002-7966-7240
Md Sanowar HossanComputational Biosciences and Chemistry Research Organization, Rajshahi, Bangladesh.
Md Shahanur ProdhanComputational Biosciences and Chemistry Research Organization, Rajshahi, Bangladesh.
Md Nahid Hasan JoyComputational Biosciences and Chemistry Research Organization, Rajshahi, Bangladesh.ORCID https://orcid.org/0009-0009-9322-2828
Muntasir Rahman SiamComputational Biosciences and Chemistry Research Organization, Rajshahi, Bangladesh.
Md Ekhtiar RahmanComputational Biosciences and Chemistry Research Organization, Rajshahi, Bangladesh.
Mohammad Nurul MatinDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.ORCID https://orcid.org/0000-0002-3594-2570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast Growth Factor Receptor 2 (FGFR2) plays a critical role in cellular proliferation and differentiation, and its dysregulation is associated with multiple cancers. This study integrates molecular docking, deep learning, pharmacokinetic profiling, and molecular dynamics (MD) simulations to identify potential FGFR2 inhibitors from a library of 1,350 phytochemicals derived from 51 anti-cancer medicinal plants that were traditionally used for anticancer purposes. Initial screening through AutoDock Vina revealed several top candidates with high binding affinities to FGFR2. The top three compounds, uralenol, glycyrol, and abyssinone II, underwent further evaluation via deep learning models, which predicted the potential efficacy of the pIC₅₀ (negative logarithm of the half-maximal inhibitory concentration) values. The ADME/T (absorption, distribution, metabolism, excretion, and toxicity) analysis confirmed favorable pharmacokinetic profiles and low toxicity risks. MD simulations validated the stability and compactness of protein-ligand complexes, with principal component analysis (PCA) and free energy landscape analyses confirming these interactions' conformational stability and thermodynamic favorability. These findings suggest that uralenol, glycyrol, and abyssinone II are potential FGFR2 inhibitors and need further experimental validation for potential therapeutic use in cancer treatment.

Indexed as

Deep LearningMolecular Dynamics SimulationPlants, MedicinalProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2HumansMolecular Docking SimulationFGFR2 protein, humanProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID41615925
PMCPMC12857956

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.